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PRELIMINARY EXPERIENCE WITH FK506 IN THORACIC TRANSPLANTATION 
FK506. a potent immunosuppressive macrolide antibiotic. 
underwent initial clinical trails in liver recipients with intrac-
table rejection or refractory drug toxicity (1, 2). The dramatic 
results achieved by this agent in urescue" therapy were foUowed 
shortly by its introduction as a primary immunosuppressant in 
kidney and liver recipients beginning in March 1989 at the 
Presbyterian University and Children's Hospital of Pittsburgh 
(3. 4). In October 1989, a prospective clinical trial was begun 
using FK506 and low-dose steroids as the sole immunosuppres-
sion in patients undergoing orthotopic cardiac transplantation. 
The preliminary results using FK506 and low-dose steroids as 
primary immunosuppression in 23 patients following cardiac 
transplantation and in 4 patients as "rescue" therapy for re-
fractory rejection or drug toxicity are reported here. 
The 23 patients (19 males. 4 females) were prospectively 
entered into this study between 8 October 1989 and 1 June 
1990. Informed consent was obtained from each patient prior 
to transplantation for the use of FK506. The age ranged from 
22 days to 54 years. in 16 adult and 7 pediatric patients. The 
etiology of cardiomyopathy included ischemic (9), idiopathic 
(7), complex congenital (5) and valvular (2). Pretransplant 
mechanical circulatory support (MCS)· in the form of the 
Novacor left ventricular assist device ILVADl (3). intraaortic 
balloon pump I rABP) (4) and extracorporeal membrane oxy-
genation I ECMOl (1), was required in 8 of the 23 patients 
(35%), Three children each had 5 prevIous thoracic operations. 
one child was on ECMO for 8 days pllor to transplantation 
followmg extensive ventncular infarction subsequent to an 
arterial switch procedure. and one child was a neonate trans-
planted at 22 days of age for hypoplastic left heart syndrome 
(HLHS) (Table 1). 
FK506 was administered intravenously for 24 to 72 hr follow-
ing transplantation at a dose of 0.15 mg/kg/day in two divided 
doses. I Fig. 1) Oral administration was begun at 0.2 mg/kg/day 
in two divided doses within 36 to 72 hr posttransplant upon 
return of gastrointestinal function. Maintenance dose to attain 
an FK506 level of 1.5 to 3 ng/ml ranged from 0.2 to 0.4 mg/kg/ 
day. Methylprednisolone i mg/kg was administered intrave-
nously in the operating room and 5 mgt kg postoperatively for 
24 hr in three divided doses. Thereafter patients received 0.15 
mg/kg/day prednisone orally once a day. Prednisone was then 
selectively tapered or discontinued based upon rejection his· 
tory. 
Rejection episodes of mild or moderate severity were prefer-
entially treated by optimizing FK506 therapy, which conS18ted 
of increasmg the oral dose of FK506 from 4 to 8 mg/day in the 
adult patlents and from 1 to 4 mg/day in the pediatric patients. 
• AbbreVlauonl: ECMO. exuacorporeal membrane oxypnation: 
HLHS. hypoplutlC left heaR syndrome: lASP. intraaorac balloon 
pump: LV AD. left venmc:uiar US1It device: MCS. mechanic:al circula-
tory support.. 
In some patients azotemia and oliguria limited the latitude with 
which to further increase FK506, particularly in the perioper-
ative period: in these patients rejection episodes were treated 
either by intravenous methylprednisolone for 24 or 48 hr or 
with an oral prednisone taper, 100 mg to 20 mg over 5 days. 
Twenty-two of the 23 patients (96%) entered into this trial 
are alive. Median follow-up was 84 days (16 to 236 days, as of 
1 June 1990). One patient died in the immediate postoperative 
period from severe and unresponsive pulmonary hypertension 
and right heart failure. No mortality due to hyperacute. acute. 
or refractory cardiac rejection was seen during the use of FK506. 
The average left ventricular ejection fraction in the group 
measured by gated nuclear scan and/or echocardiography was 
70% (range 58-75%) at the time of longest follow-up. 
Four serious infections in 3 patients were present prior to 
cardiac transplantation. One patient had two pretransplant 
infections: during LABP support this patient was treated for an 
episode of staphylococcal line sepsis. This same patient had 
pulmonary emboli and infarctions and eventually required No-
vacor LV AD support. At the time of transplantation. 3 weeks 
following LV AD the wound culture was positive for candida. 
Amphotericin therapy was administered for 5 weeks after trans-
plantation. and the sternal wound healed without incident. One 
neonatal patient had several episodes of line sepsis. This pa-
tient received no steroids during the postoperative penod. 
FK506 being his only immunosuppressant. No episodes of 
cardiac rejection had been detected on routine weekly endo· 
myocardial biopsies. The neonate With HLHS had several 
episodes of line sepsis. The other patient with a pretransplant 
infection was treated for a Klebsiella pneumonia during IABP 
support for 8 days when a donor heart became available. After 
transplantation. this patient required rehospitalization for hy-
perglycemia. dehydration. and diarrhea. the work-up of which 
revealed CMV gastroenteritis. Ganciclovir therapy resulted in 
complete resolution of symptoms and no recurrence has been 
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noted. Two patients. both children. have had culture-negative 
episodes of sinusitis. One other child has developed a pneu-
monia and is recovering; the etiologic agent has not yet been 
identified. No other major or minor infections have occurred 
to date. 
As would be expected with random matching, poor HLA 
compatibility was present in all but 2 recipients. One recipient 
received her donor heart from her sister. who had suffered brain 
death from a cerebrovascular accident. This rare scenario re-
sulted in a six-antigen match. All patients had a panel reactive 
antibody of 0% except for 3 patients: 2 had a PRA of 3% and 
one patient had a PRA of 20%. 
During this early follow-up period there have been ten epi-
sodes of moderate or severe rejection (Billingham grade 3 or 
greater) in 8 patients. (Fig. 2) Three episodes were treated with 
one or two doses of methylprednisolone \500 mg i.v.). Three 
episodes were treated with a 10-20% increase in the oral FK506 
dosage. Three patients were treated with a prednisone taper. 
All nine of these episodes resolved with these respective treat-
ments. One patient was treated with OKT3 and is the only 
patlent in whom azathioprine was added. 
The incidence of rejection treated with aultlIlented immuno-
suppression within the first 90 days posttransplant in patients 
on FK506 immunotherapy was 0.22 episodes per patient. (Fig. 
3) This compared favorably to our most recent prospective 
randomized trial using conventional cyclosporine-based triple-
drug immunotherapy comparing rabbit antithymocyte globulin 
(RATGl vs. OKT3 prophylaxis. \5) The incidence of treated 
rejection in the first 90 days following transplant in the RATG 
group (n = ::19) was 0.42 episodes per patient and in the OKT3 
(n ,.. 43) group was 1.2 episodes per patient. while 9 patients 
receiving no immunoprophylaxis had 1.55 episodes of treated 
rejection. 
The high FK506 levels attained in the perioperative period 
by administering intravenous drug overlapped with the insti-
tution of oral therapy uniformly exacts a price to be paid in 
terms of renal functlon in cardiac transplant reCipients. 
Although 3 pauents had no Significant alteration in urine 
output or renal function. the remainder sutfered significant 
oliguria and azotemia. which peaked at an average on the 6th 
postoperative day (mean event :t 1). Renal function returned 
toward. but not back to, preoperative levels in all patients. 
around the 14th postoperative day (mean event :t 1). 
Two of the 23 patients in this trial reqUired dialysis. The 
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first was the patient transplanted at 22 days of age for HLHS. 
This small patient suffered multiple bouts oi line sepsis. nearlv 
constant anubiotic therapy inciuding vancomvcln. and vena 
caval and renal vein thrombosis. Peritoneal dialysis was insti-
tuted during the 3rd postoperative week and the child and his 
renal function are recovering. This patient is exciuded from the 
analysis of renal function in the group as a whole because of 
his multiple complicating variables. The other patient who has 
required dialysis suffered a cardiac arrest on induction of anes-
thesia. which required emergency placement of an IABP. 
FK506 levels attained in the early postoperative period were 
also very high. This patient's renal function also is returning 
toward normal. In Figures 4 and 5 the serum BUN and creati-
nine levels in patients on FK506 immunotherapy were com· 
pared with those of the 40 patients on cyciosporine immuno-
therapy transplanted at our institution pnor to October 1989. 
Hypenension is notably rate in patients following cardiac 
transplantation treated with FK506 and low·dose steroids. Onlv 
:1 of 15 patients (20%) on FK506. followed for greater than J 
months. have required antihypenenslve treatment. and all are 
well controlled on a single agent. In contrast. of the 40 prevIOus 
cardiac transplant recipients treated with cyclosporine-based 
triple-drug immunotherapy, :28 (70%) required at least smgle-
drug antihypenensive therapy tFig. 6). This difference IS sta· 
tistically significant (P<O.OOl). 
Two of the 23 patients developed insulin·dependent diabetes 
following cardiac transplantation. One patient. mentioned 
above. returned with a CMV enteritis and reqUired steroid 
treatment for rejection; hyperglycemia was lirst evident on this 
readmission and has required insulin for control. Of note IS this 
patient's positive OR3 locus. One other patient. also still on 
steroids. has required insulin following transplant. 
Continuous monitoring of hematologic and coagulation in· 
dices. as well as liver function. cholesterol. triglycerides. LDL . 
HDL. and VLDL have failed to reveal any abnormalities in our 
patients at this intervaL Only 2 of 22 patients have abnormal 
uric acid levels. one of whom had gout pretransplantatlon. 
To date. 4 patients who have had refractory cardiac rejection 
on augmented conventional immunosuppression have under-
gone "rescue" therapy with FK506. Two or these patients are 
from our center. One patient with an elevated PRA wu retrans-
planted at 6 years due to chroniC rejection. Subsequent to 
retranaplantation. on mamtenance cyclosponne she smfered 
r 
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"r hypertenSion. 
continued rejection despite OKT3 prophylaxis and treatment 
With sterOids and RATG. She was SWitched to FK506 after 4 
months and her prednisone has been tapered to 5 mg. She has 
had two episodes 01 3+ rejection since her SWitch: however. 
these have cleared with increased oral dose fK506. Her cush-
I ngold habitus has melted away with her loss 01 27 pounds. and 
she is very strikingly pleased with her "new" self. The second 
TABLE 1. FK506 immunosuppression m orthotopic cardiac 
tranapiantatlon. 10/89 to 6190 
Male/female 
Pediatric 1<18) 
Pretransplant MeS 
Follow-up 1 days I 
Range 
Median 
Patiellts tn = ~P1 
19/4 
j 
8 
(35%) 
Davt 
16-236 
84 
of our patients to undergo a switch to FK506 is a pediatric 
patient with hypenension. hypercholesterolemia. severe steroid 
morbidity, and persistent grade 2 rejection. Steroids have been 
tapered to 5 mg and at this early interval cardiac rejection is 
resolving. Resolution of his other drug-related toxicities are 
anticipated. 
Two other patients have undergone cardiac rescue with 
FK506. after repeated attempts to reverse cardiac rejection 
with conventional rescue therapy. Persistent rejection has been 
reversed in both patients with subsequent normalization ot 
their endomyocardial biopsies. 
Two patients with cystic fibrosis have undergone double-lung 
transplantation and one patient with Eisenmenger's physiology 
has had a heart-lung transplant with FK506 as the sale im-
munosuppressant. No steroids have been used with the excep-
tion of a prednisone taper given to one patient several months 
after transplant. All 3 patients are surviving with a median 
follow·up of 213 days. 
Serious or even mild side eifects from FK506 have been 
exceedingly rare with the exception of renal dysfunction de-
tailed above. During the intravenous administration. tlushing, 
nausea. and anorexia have been encountered occasionallv. The 
oral form of FK506 is very well tolerated. and the only reported 
side effects. even after extensive and routine pattent question· 
ing, have been tingling and temperature malsensatlon In the 
bands and feet. These latter symptoms are most often assocI-
ated with toxicity and high blood levels. Only one patient has 
been removed from FK506 therapy due to an allergtc-type 
pneumonitis: however, it remams unclear if this is related to 
FK therapy, and the child is to be placed back on FK506 in the 
near future and pulmonary functions WIll be followed with great 
interest. 
:-Jotably absent in these patients have been complaints of 
gingival hyperplasia or hirsutism. 
Our preliminary results with FK506 and low-dose sterOIds 
for cardiac transplantation are extremelv promising. During 
this very early follow-up period FK506 and low-dose sterOids 
attain immunosuppression at least comparable. if not superIOr. 
to the very best immunosuppressive therapy of the past decade 
employed at the Universltv of Pittsburgh. using RATG immu-
noprophylaxis and cyclosporlne-based triple-drug Immunother· 
apy. Not immediately apparent in these results is a signuicam 
flexibility in the clinical use 01 FK506. In the pnmarv group 
and in the "rescue" group mild and moderate eplsories 01 
rejection have been reversed with small increases in oral FK506 
dosa~K 
The most obvious toxicity of FK506 was renal impairment. 
CertaInly some 01 the azotemia and oli~na had occurre<l in 
our attempts to attain high fK506 levels early on 101i0WIng 
transplantatlon. In the future. as was expenenced with cyclo· 
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sporine. some modification of the perioperative use of FK506 
may diminish early renal dysfunction. The dramatic absence 
of hypenension in this group of patients and the very well 
tolerated form of oral FK506 are encouraging for better pres-
ervation of long-term renal function. Initial evaluation of the 
histology from renal biopsies of kidney transplant recipients 
showed no specific pathology attributable to FK506 (Demetria 
AJ. verbal communication I. The powerful immunosuppressant 
effects of FK506 are underscored in four rather dramatic areas. 
First FK506 appeared to be able to reverse cardiac rejection 
that had been refractory to all other known forms of therapy. 
Second. the pediatric group of patients. particularly trouble-
some compared to their adult counterparts in controlling rejec-
tion, have fared extremely well. and 6 of the 7 children are on 
no steroids. Third. FK506 introduces a new degree of flexibility 
in immunosuppressant management in the ability to merely 
increase oral dosage and reverse moderate episodes of rejection. 
Finally, the potential benefits of FK506-based immunotherapy, 
with little need for large steroid doses and nonspecific bone 
marrow suppressants. may be realized in decreased infection 
rates. 
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A COMPARISON OF IN VIVO RESPONSES TO CYCLOSPORINE. FK506. AND oAmAMvCf~ FOLLOWING 
ALLOGENEIC IMMUNE CHALLENGEI 
Although substantial progress has resulted in organ trans-
plantation becoming the therapy of choice lor many causes of 
end-stage organ system failure. the ability to safely control 
allogratt reJection has remained a major obstacle to more uni-
form success. Recently, much enthusiasm has surrounded the 
discovery of the immunosuppressive propenies of FK506. a 
naturally occurring macrolide produced by Streptomyces tsu-
kubaensis. discovered in Japan in 1984 (1). Experimental ob-
servations documenting potent immunosuppressive effects (2) 
quickly led to organ transplantation trials in a number of 
experimental animals (3-6). Several investigators corroborated 
the potent immunosuppressive propenies associated with 
FK506. and its mechanism of action. which is similar to cyclo-
sporine. seems to involve inhibition of transcriptional events 
imponant to lymphokine gene activation. As with CsA. binding 
to an intracellular cis-trans prolyl isomerase has been observed 
(7. 8). Substantial toxicities. including severe arteritis. were 
observed in dogs receiving the sgent (4 I. while others found 
this not to be a substantial problem when baboons underwent 
transplantation usmg FK506 (51. The first human trials with 
FK506 have been initiated at the University of Pittsburgh (9. 
10). however. it remains premature to predict the role that this 
promising agent will play in the clinical setting. 
: This work w •• presented in part at the 16th Scienufic Meetin, oi 
the Amencan Society ot TranaplaDt Surpom. (;hic:qo, illinois. May 
30.1990. 
A structurally similar compound. rapamvcin IRAPAI: also 
a naturally occurring macrolide isolated from S hygroscopicus 
was discovered at the Wveth-Averst Research Laboratories in 
the middle 1970s (II), Early tindings Indicated that RAPA too 
exhibited immunosuppressive propenies. and it was shown to 
be effective in the therapy of experimentally induced autoim-
mune diseases (12). The structural similarities with FK506 
renewed interest in the immunosuppressive propenies of 
RAPA. and its possible role as an effective agent for antirejec-
tion prophylaxis has become the subject of several reports. 
Morris and Meiser (13) reponed that rat and murine cardiac 
allograft survival was prolonged under RAP A immunosuppres-
sion-and. shonly thereafter. Caine et a1. (14) demonstrated 
similar prolongation of both rat and pig cardiac allograits using 
RAPA. 
We have begun investigations into the effects of RAPA on 
in vivo allogeneic responses. Allogeneic (DBA/2. H-2") or syn-
geneic splenocytes were harvested. prepared as single-cell sus-
pensions. and administered into each rear tootpad of C5iBL/6 
(H-2b ) mice that were not immunosuppressed. or were immu-
nosuppressed with CsA (5 mg/kg/day. i.p.). FK506 <0.5 mg/kg/ 
day, i.p.), or RAPA 10.5 mg/kg/gday, i.p.). Immunosuppression 
wu begun on the day prior. and continued for 3 days following 
rear footpad challenge under chloral hydrate anesthesia With 
• Abbl'8Y1atlOna: CYP. cyc:iophilin: RAPA. rapa.myan. 
